Physician profile

Samer Obri

Internal Medicine · Defiance, OH

NPI 1700879657

$5,787.66

in general payments reported to CMS, 2019-2025

41 companies · $845 in 2025

The $845 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,993.27

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $977.59 2019-2025 Ozempic, Rybelsus, Wegovy
Dexcom, INC. $507.88 2021-2025 Dexcom G6 Transmitter
Astrazeneca Pharmaceuticals Lp $483.58 2019-2025 Airsupra, Farxiga, Breztri
Janssen Pharmaceuticals, INC $471.48 2019-2022
Abbvie INC. $469.94 2022-2025
Amgen INC. $408.37 2019-2025 Evenity, Repatha, Otezla
Pfizer INC. $288.10 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $217.54 2019-2024 Jardiance
Bayer Healthcare Pharmaceuticals INC. $196.98 2022-2024
Inari Medical, INC. $191.52 2023 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Sanofi-Aventis U.S. LLC $186.02 2019-2020
Novartis Pharmaceuticals Corporation $164.99 2019-2024
Glaxosmithkline, LLC. $152.99 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Lilly USA, LLC $142.28 2019-2025 Mounjaro, Jardiance
Sunovion Pharmaceuticals INC. $124.62 2019
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Integra Lifesciences Corporation $87.52 2024 Biofix, Biodrestore, Biodoptix
Corcept Therapeutics $81.69 2024-2025 Korlym
Shield Therapeutics INC $50.43 2022-2023 Accrufer
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $45.00 2025 Caplyta
Kowa Pharmaceuticals America, INC. $41.35 2022-2023 Seglentis, Livalo
Lundbeck LLC $37.85 2023-2024 Rexulti
Teva Pharmaceuticals USA, INC. $36.70 2019-2020
Exact Sciences Corporation $36.48 2024 Cologuard Collection Kit
Biohaven Pharmaceutical Holding Company Ltd. $36.11 2022
Phathom Pharmaceuticals, INC. $34.68 2024 Voquezna
Abbott Laboratories $32.18 2024-2025 Freestyle Libre 3
Astellas Pharma US INC $27.99 2019-2020
Takeda Pharmaceuticals U.S.A., INC. $26.42 2019-2022
Eisai INC. $25.13 2024
Amarin Pharma, INC. $23.98 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $22.37 2025 Xifaxan
Axsome Therapeutics, INC. $21.62 2024 Auvelity
Xeris Pharmaceuticals, INC. $19.30 2022
Allergan, INC. $17.55 2020
Viatris Specialty LLC $16.74 2025 Yupelri
Mannkind Corporation $15.00 2020
Currax Pharmaceuticals LLC $14.06 2024 Contrave
Phadia US INC. $13.74 2023 Immunocap
Mylan Specialty L.P. $13.63 2024 Yupelri
Otsuka America Pharmaceutical, INC. $13.26 2023 Rexulti
Daiichi Sankyo INC. $13.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Samer Obri

$5,787.66

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC
Context
The $845 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/77645/samer-obri

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.